{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:13:43Z","timestamp":1760188423751,"version":"3.40.5"},"reference-count":23,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,7,1]]},"abstract":"<jats:p>Antibodies to \u03b22-glycoprotein I (anti-\u03b22GPI) have been associated with recurrent thrombosis and pregnancy morbidity. However, the prevalence of anti-\u03b22GPI in children suffering from cerebral infarction is unknown. We report on a 20-month-old boy who had an ischemic stroke, secondary to antiphospholipid syndrome with high titers of immunoglobulin G anti-\u03b22GPI (first titer: 132 U; second titer 6 weeks later: 350 U; normal range: 0\u2013100 U). Anticardiolipin antibodies and lupus anticoagulant tests were negative. All other causes of infarction were excluded. Laboratory studies showed anti-\u03b22GPI IgG levels of 164 U and 216 U at 6 months and 2 years, respectively, after the onset. The patient received treatment with low-dose aspirin. To our knowledge, this is the first reported case of childhood ischemic stroke with only anti-\u03b22GPI but no antibodies detectable in standard antiphospholipid assays. This case supports the recommendation of others to search for these antibodies in the presence of strong clinical suspicion of antiphospholipid syndrome, when anticardiolipin antibodies and lupus anticoagulant tests are negative.<\/jats:p>","DOI":"10.1542\/peds.112.1.188","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:43:47Z","timestamp":1092444227000},"page":"188-190","source":"Crossref","is-referenced-by-count":7,"title":["Anti-\u03b22-Glycoprotein I Antibodies and Ischemic Stroke in a 20-Month-Old Boy"],"prefix":"10.1542","volume":"112","author":[{"given":"Eustathia","family":"Katsarou","sequence":"first","affiliation":[{"name":"Department of Neurology&#x2028; Panagiotis and Aglai\u0308a Kyriakou Children\u2019s Hospital&#x2028; Athens, 11527 Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achilleas","family":"Attilakos","sequence":"additional","affiliation":[{"name":"Second State Department of Pediatrics&#x2028; Panagiotis and Aglai\u0308a Kyriakou Children\u2019s Hospital&#x2028; Athens, 11527 Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smaragdi","family":"Fessatou","sequence":"additional","affiliation":[{"name":"Second State Department of Pediatrics&#x2028; Panagiotis and Aglai\u0308a Kyriakou Children\u2019s Hospital&#x2028; Athens, 11527 Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heleni","family":"Tsapra","sequence":"additional","affiliation":[{"name":"Second State Department of Pediatrics&#x2028; Panagiotis and Aglai\u0308a Kyriakou Children\u2019s Hospital&#x2028; Athens, 11527 Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasiliki","family":"Tzavara","sequence":"additional","affiliation":[{"name":"Immunology Department&#x2028; General Hospital of Athens&#x2028; Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Dracou","sequence":"additional","affiliation":[{"name":"Second State Department of Pediatrics and Outpatient Pediatric Rheumatology Clinic&#x2028; Panagiotis and Aglai\u0308a Kyriakou Children\u2019s Hospital&#x2028; Athens, 11527 Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2003,7,1]]},"reference":[{"key":"2021121003384652900_R1","doi-asserted-by":"crossref","unstructured":"Lynch JK, Hirtz DG, De Veber G, Nelson KB. Report of the National Institute of Neurological Disorders and Stroke workshop on perinatal and childhood stroke. Pediatrics.2002;109:116\u2013123","DOI":"10.1542\/peds.109.1.116"},{"key":"2021121003384652900_R2","doi-asserted-by":"crossref","unstructured":"Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology.1993;43:2069\u20132073","DOI":"10.1212\/WNL.43.10.2069"},{"key":"2021121003384652900_R3","doi-asserted-by":"crossref","unstructured":"Von Scheven E, Athreya BH, Rose CD, Goldsmith DP, Morton L. Clinical characteristics of antiphospholipid antibody syndrome in children. J Pediatr.1996;129:339\u2013345","DOI":"10.1016\/S0022-3476(96)70064-1"},{"key":"2021121003384652900_R4","doi-asserted-by":"crossref","unstructured":"Angelini L, Ravelli A, Capolari R, Rumi V, Nardocci N, Martini A. High prevalence of antiphospholipid antibodies in children with idiopathic cerebral ischemia. Pediatrics.1994;94:500\u2013503","DOI":"10.1542\/peds.94.4.500"},{"key":"2021121003384652900_R5","unstructured":"Cabiedes J, Cabral AR, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-\u03b22-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol.1995;22:1899\u20131906"},{"key":"2021121003384652900_R6","unstructured":"Cabral AR, Cabiedes J, Alarcon-Segovia D. Antibodies to phospholipid-free \u03b22-glycoprotein-I in patients with primary antiphospholipid syndrome. J Rheumatol.1995;22:1894\u20131898"},{"key":"2021121003384652900_R7","doi-asserted-by":"crossref","unstructured":"Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet.1990;335:1544\u20131547","DOI":"10.1016\/0140-6736(90)91374-J"},{"key":"2021121003384652900_R8","doi-asserted-by":"crossref","unstructured":"McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: \u03b22-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A.1990;87:4120\u20134124","DOI":"10.1073\/pnas.87.11.4120"},{"key":"2021121003384652900_R9","doi-asserted-by":"crossref","unstructured":"Matsuura E, Igarashi Y, Fujimoto M, Ichikawa T, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet.1990;336:177\u2013178","DOI":"10.1016\/0140-6736(90)91697-9"},{"key":"2021121003384652900_R10","doi-asserted-by":"crossref","unstructured":"Carreras LO, Ricardo R, Forastiero RR, Martinuzzo ME. Which are the best biological markers of the antiphospholipid syndrome?J Autoimmun.2000;15:163\u2013172","DOI":"10.1006\/jaut.2000.0401"},{"key":"2021121003384652900_R11","unstructured":"Vlachoyiannopoulos PG, Petrovas C, Tektonidou M, Krilis S, Moutsopoulos HM. Antibodies to \u03b22-glycoprotein I: urea resistance, binding specificity, and association with thrombosis. J Clin Immunol.1998;18:380\u2013391"},{"key":"2021121003384652900_R12","doi-asserted-by":"crossref","unstructured":"Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum.1999;42:1309\u20131311","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F"},{"key":"2021121003384652900_R13","doi-asserted-by":"crossref","unstructured":"Cabral AR, Amigo MC, Cabiedes J, Alarcon-Segovia D. The antiphospholipid\/cofactor syndromes: a primary variant with antibodies to \u03b22-glycoprotein I but no antibodies detectable in standard antiphospholipid assays. Am J Med.1996;101:472\u2013481","DOI":"10.1016\/S0002-9343(96)00254-9"},{"key":"2021121003384652900_R14","unstructured":"Picillo U, Marcialis MR, Italiano G. Antibodies to \u03b22-glycoprotein I in anticardiolipin negative patients. J Rheumatol.1998;25:1440\u20131442"},{"key":"2021121003384652900_R15","doi-asserted-by":"crossref","unstructured":"Roubey RA. Immunology of the antiphospholipid syndrome. [review]. Arthritis Rheum.1996;39:1444\u20131454","DOI":"10.1002\/art.1780390903"},{"key":"2021121003384652900_R16","doi-asserted-by":"crossref","unstructured":"Olson JC, Konkol RJ, Gill JC, Dobyns CT, Coull BM. Childhood stroke and lupus anticoagulant. Pediatr Neurol.1994;10:54\u201357","DOI":"10.1016\/0887-8994(94)90068-X"},{"key":"2021121003384652900_R17","unstructured":"Roddy SM, Giang DW. Antiphospholipid antibodies and stroke in an infant. Pediatrics.1991;87:933\u2013935"},{"key":"2021121003384652900_R18","doi-asserted-by":"crossref","unstructured":"Di Nucci GD, Mariani G, Arcieri P, et al. Antiphospholipid syndrome in young patients. Two cases of cerebral ischaemic accidents. Eur J Pediatr.1995;154:334","DOI":"10.1007\/BF01957376"},{"key":"2021121003384652900_R19","doi-asserted-by":"crossref","unstructured":"Kenet G, Sadetzki S, Murad H, et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke.2000;31:1283\u20131288","DOI":"10.1161\/01.STR.31.6.1283"},{"key":"2021121003384652900_R20","doi-asserted-by":"crossref","unstructured":"Von Scheven E, Glidden DV, Elder ME. Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum.2002;47:414\u2013420","DOI":"10.1002\/art.10510"},{"key":"2021121003384652900_R21","doi-asserted-by":"crossref","unstructured":"Gomez-Pacheco L, Villa AR, Drenkard C, Cabiedes J, Cabral AR, Alarcon-Segovia D. Serum anti-\u03b22-glycoprotein I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus and the antiphospholipid syndrome. Am J Med.1999;106:417\u2013423","DOI":"10.1016\/S0002-9343(99)00053-4"},{"key":"2021121003384652900_R22","unstructured":"Myones BL, McCurdy D. The antiphospholipid syndrome: immunologic and clinical aspects. Clinical spectrum and treatment. [review]. J Rheumatol.2000;27(suppl):20\u201328"},{"key":"2021121003384652900_R23","doi-asserted-by":"crossref","unstructured":"Mohr JP, Thompson JLP, Lasar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med.2001;345:1444\u20131451","DOI":"10.1056\/NEJMoa011258"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/112\/1\/188\/1002517\/pe0703000188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/112\/1\/188\/1002517\/pe0703000188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T05:39:41Z","timestamp":1682746781000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/112\/1\/188\/63370\/Anti-2-Glycoprotein-I-Antibodies-and-Ischemic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7,1]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2003,7,1]]},"published-print":{"date-parts":[[2003,7,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.112.1.188","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2003,7,1]]}}}